Biomea Fusion, Inc. Deferred Offering Costs
Biomea Fusion, Inc. (BMEA) had Deferred Offering Costs of $0 as of 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2022-02-28
- 2021-12-31: Deferred Offering Costs $0.00.
- 2021-03-31: Deferred Offering Costs $1.60M.
- 2020-12-31: Deferred Offering Costs $29.00K; Deferred Offering Costs as first filed $0.00.
| Period end | Deferred Offering Costs | Deferred Offering Costs as first filed |
|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | |
| 2021-03-31 | $1.60M 10-Q · filed 2021-05-27 | |
| 2020-12-31 | $29.00K 10-K · filed 2022-02-28 | $0.00 10-Q · filed 2021-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |